```
=> File .Biotech
=> s cyclosporine? and (ethano? or ethyl(w)alcohol? or polyethylene(w)glycer? or
oleate? or oil) and emulsion?
L1        1256 CYCLOSPORINE? AND (ETHANO? OR ETHYL(W) ALCOHOL? OR POLYETHYLENE(
               W) GLYCER? OR OLEATE? OR OIL) AND EMULSION?

=> s l1 and (medic? or therap? or drug? or pharm?)
   3 FILES SEARCHED...
   5 FILES SEARCHED...
L2        1254 L1 AND (MEDIC? OR THERAP? OR DRUG? OR PHARM?)

=> s l2 and (oral? or mouth or per os)
L3        1103 L2 AND (ORAL? OR MOUTH OR PER OS)

=> s l3 and (spontaneous(w)emulsion?)
L4           3 L3 AND (SPONTANEOUS(W) EMULSION?)

=> d l4 1-3 bib ab

L4   ANSWER 1 OF 3  CAPLUS  COPYRIGHT 2003 ACS on STN
AN   2003:173386  CAPLUS
DN   138:193311
TI   Spontaneous emulsions containing cyclosporine
IN   Egbaria, Kamel F.; Groves, Michael J.
PA   Morton Grove Pharmaceuticals, Inc., USA
SO   PCT Int. Appl., 9 pp.
     CODEN: PIXXD2
DT   Patent
LA   English
FAN.CNT 1
     PATENT NO.        KIND  DATE           APPLICATION NO.  DATE
     ---------------   ----  --------       ---------------  --------
PI   WO 2003017947     A2    20030306       WO 2002-US27531  20020829
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
             CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
             GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
             LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
             PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ,
             UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU,
             TJ, TM
         RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG,
             CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL,
             PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR,
             NE, SN, TD, TG
     US 2003049280     A1    20030313       US 2001-943687   20010831
PRAI US 2001-943687    A     20010831
AB   A pharmaceutical compn. contains cyclosporine as the
     active ingredient. More specifically, the compn. is an orally
     administered pharmaceutical formulation in the form of a
     spontaneous emulsion comprising cyclosporine,
     ethanol, Et oleate and polyoxyethylene glycerol
     trioleate. A method for prepg. an orally administered
     pharmaceutical compn. involves first dissolving
     cyclosporine in ethanol. Polyoxyethylene glycerol
     trioleate and an oil component are then added, mixed and dild.
     in an aq. media to form a spontaneous emulsion. Thus,
     a formulation contained cyclosporine 10, EtOH 18, PEG trioleate
     24.5, and Et oleate 47.5 g.

L4   ANSWER 2 OF 3  USPATFULL on STN
AN     2003:70995  USPATFULL
TI     Spontaneous emulsions containing
       cyclosporine
IN     Egbaria, Kamel F., Gurnee, IL, UNITED STATES
```

Groves, Michael J., Deerfield, IL, UNITED STATES
PI US 2003049280 A1 20030313
AI US 2001-943687 A1 20010831 (9)
DT Utility
FS APPLICATION
LREP RATNER AND PRESTIA, Suite 301, One Westlakes, Berwyn, P.O. Box 980, Valley Forge, PA, 19482-0980
CLMN Number of Claims: 30
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 288
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A **pharmaceutical** composition contains **cyclosporine** as the active ingredient. More specifically, the composition is an **orally** administered **pharmaceutical** formulation in the form of a **spontaneous emulsion** comprising **cyclosporine**, **ethanol** ethyl **oleate** and polyoxyethylene glycerol trioleate. A method for preparing an **orally** administered **pharmaceutical** composition involves first dissolving **cyclosporine** in **ethanol**. Polyoxyethylene glycerol trioleate and an **oil** component are then added, mixed and diluted in an aqueous media to form a **spontaneous emulsion**.

L4 ANSWER 3 OF 3 WPIDS COPYRIGHT 2003 THOMSON DERWENT on STN
AN 2003-381396 [36] WPIDS
DNC C2003-101154
TI An **orally** administered **cyclosporine** composition which forms a **spontaneous emulsion** comprises **cyclosporine**, **ethanol**, polyoxyethyleneglycerol trioleate and an **oil**.
DC A96 B04 B07
IN EGBARIA, K F; GROVES, M J
PA (EGBA-I) EGBARIA K F; (GROV-I) GROVES M J; (MORT-N) MORTON GROVE PHARM INC
CYC 101
PI WO 2003017947 A2 20030306 (200336)* EN 9p
RW: AT BE BG CH CY CZ DE DK EA EE ES FI FR GB GH GM GR IE IT KE LS LU MC MW MZ NL OA PT SD SE SK SL SZ TR TZ UG ZM ZW
W: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG UZ VC VN YU ZA ZM ZW
US 2003049280 A1 20030313 (200336)
ADT WO 2003017947 A2 WO 2002-US27531 20020829; US 2003049280 A1 US 2001-943687 20010831
PRAI US 2001-943687 20010831
AB WO2003017947 A UPAB: 20030609
NOVELTY - An **orally** administered composition comprising **cyclosporine**, **ethanol**, polyoxyethylene glycerol trioleate and an **oil** component is new.
DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included for:
(1) an **orally** administered composition comprising **cyclosporine**, **ethanol**, polyoxyethylene glycerol trioleate and ethyl **oleate** in a weight ratio of 5:18:25.9:50.1 to about 15:16:23.1:44.9; and
(2) preparing an **orally** administered composition by dissolving **cyclosporine** in **ethanol** to form a solution, combining polyoxyethylene glycerol trioleate and an **oil** component with the solution to form a mixture and diluting the mixture with an aqueous media to allow formation of a **spontaneous emulsion**.
ACTIVITY - Immunosuppressive; Antiinflammatory; Protozoacide.
MECHANISM OF ACTION - None given.
USE - **Cyclosporines** have immunosuppressive and

anti-inflammatory activity. They may be used to suppress immunological reactions to transplanted organs or tissue, to suppress hematological disorders e.g. anemia, various autoimmune diseases e.g. systemic lupus erythematosus and idiopathic malabsorption syndrome and inflammatory diseases e.g. arthritis and rheumatoid disorders. **Cyclosporine** is also used to treat protozoal diseases e.g. malaria and schistosomiasis and it has also been used recently in chemotherapy.

ADVANTAGE - **Cyclosporine** has low water solubility and so is difficult to formulate for **oral** administration, the present composition overcomes this disadvantage.

Dwg.0/0

=> s l3 and (self emulsifying drug deliver system or SEDDS)
L5 8 L3 AND (SELF EMULSIFYING DRUG DELIVER SYSTEM OR SEDDS)

=> d l5 1-8 bib ab

L5 ANSWER 1 OF 8 USPATFULL on STN
AN 2003:213290 USPATFULL
TI Eutectic-based self-nanoemulsified **drug** delivery system
IN Khan, Mansoor A., Amarillo, TX, UNITED STATES
Nazzal, Sami, Amarillo, TX, UNITED STATES
PI US 2003147927 A1 20030807
AI US 2002-293932 A1 20021114 (10)
PRAI US 2001-331292P 20011114 (60)
DT Utility
FS APPLICATION
LREP JONES, TULLAR & COOPER, P.C., P.O. BOX 2266 EADS STATION, ARLINGTON, VA, 22202
CLMN Number of Claims: 20
ECL Exemplary Claim: 1
DRWN 12 Drawing Page(s)
LN.CNT 1108
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A eutectic-based self-nanoemulsified **drug** delivery system (SNEDDS) is formulated from polyoxyl 35 castor **oil** (Cremophor), medium chain mono- and diglycerides (capmul), essential oils, and a **pharmacologically** effective **drug**. The preferred **pharmacologically** effective **drug** is a poorly water soluble **drug**, such as ubiquinone (CoQ.sub.10). The SNEDDS can be further incorporated into a powder to produce a solid dosage form. The solid dosage form contains the SNEDDS, a copolymer of vinylpyrrolidone and vinyl acetate (Kollidon VA 64), maltodextrin, and microcrystalline cellulose (MCC).

L5 ANSWER 2 OF 8 USPATFULL on STN
AN 2003:85866 USPATFULL
TI Dispersions for the formulation of slightly or poorly soluble agents
IN Muller, Rainer H., Berlin, GERMANY, FEDERAL REPUBLIC OF
PI US 2003059470 A1 20030327
AI US 2001-915549 A1 20010727 (9)
PRAI DE 2000-DE10036871 20000728
DT Utility
FS APPLICATION
LREP MANELLI DENISON & SELTER, 2000 M STREET NW SUITE 700, WASHINGTON, DC, 20036-3307
CLMN Number of Claims: 148
ECL Exemplary Claim: 1
DRWN 6 Drawing Page(s)
LN.CNT 1511
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides a dispersion having an oily phase, an aqueous phase, in the form of an **oil**-in-water **emulsion** or a water-in-**oil** **emulsion**, and at least one active

ingredient that is only slightly or with difficulty soluble in the oily phase and the aqueous phase. The dispersion is free from toxicologically dangerous organic solvents. The dispersion contains the active ingredient dissolved in a quantity that is greater than the quantity which results additively from its maximum solubility in the oily and the aqueous phase of the **emulsion** prior to forming the **emulsion**.

L5 ANSWER 3 OF 8 USPATFULL on STN
AN 2003:70995 USPATFULL
TI Spontaneous **emulsions** containing **cyclosporine**
IN Egbaria, Kamel F., Gurnee, IL, UNITED STATES
Groves, Michael J., Deerfield, IL, UNITED STATES
PI US 2003049280 A1 20030313
AI US 2001-943687 A1 20010831 (9)
DT Utility
FS APPLICATION
LREP RATNER AND PRESTIA, Suite 301, One Westlakes, Berwyn, P.O. Box 980, Valley Forge, PA, 19482-0980
CLMN Number of Claims: 30
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 288
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A **pharmaceutical** composition contains **cyclosporine** as the active ingredient. More specifically, the composition is an **orally** administered **pharmaceutical** formulation in the form of a spontaneous **emulsion** comprising **cyclosporine** , **ethanol** ethyl **oleate** and polyoxyethylene glycerol trioleate. A method for preparing an **orally** administered **pharmaceutical** composition involves first dissolving **cyclosporine** in **ethanol**. Polyoxyethylene glycerol trioleate and an **oil** component are then added, mixed and diluted in an aqueous media to form a spontaneous **emulsion**.

L5 ANSWER 4 OF 8 USPATFULL on STN
AN 2002:332743 USPATFULL
TI Kinase inhibitors
IN Armistead, David M., Sudbury, MA, United States
Bemis, Jean E., Arlington, MA, United States
Elbaum, Daniel, Newton, MA, United States
Habgood, Gregory J., Merrimac, MA, United States
Novak, Perry M., Milford, MA, United States
Nunes, Joseph J., Andover, MA, United States
Toledo-Sherman, Leticia M., Somerville, MA, United States
PA Amgen Inc., Thousand Oaks, CA, United States (U.S. corporation)
PI US 6495558 B1 20021217
AI US 2000-528976 20000321 (9)
RLI Continuation-in-part of Ser. No. US 2000-488582, filed on 21 Jan 2000, now abandoned
PRAI US 1999-116697P 19990122 (60)
DT Utility
FS GRANTED
EXNAM Primary Examiner: Rao, Deepak R.
LREP Ungemach, Frank S., Watt, Stuart L.
CLMN Number of Claims: 5
ECL Exemplary Claim: 1
DRWN 0 Drawing Figure(s); 0 Drawing Page(s)
LN.CNT 2503
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention relates to inhibitors of kinases, compositions comprising the inhibitors, and methods of using the inhibitors and inhibitor compositions. The inhibitors and compositions comprising them are useful for treating disease or disease symptoms. The invention also provides for methods of making kinase inhibitor compounds, methods of inhibiting

kinase activity, and methods for treating disease or disease symptoms.

L5 ANSWER 5 OF 8 USPATFULL on STN
AN 2002:209136 USPATFULL
TI Self-emulsifying compositions for **drugs** poorly soluble in water
IN Mulye, Nirmal, Long Beach, NY, United States
PA Pharmasolutions, Inc., Cranbury, NJ, United States (U.S. corporation)
PI US 6436430 B1 20020820
AI US 1999-459299 19991210 (9)
PRAI US 1998-111951P 19981211 (60)
DT Utility
FS GRANTED
EXNAM Primary Examiner: Travers, Russell; Assistant Examiner: Wells, Lauren Q.
LREP Scully, Scott, Murphy & Presser
CLMN Number of Claims: 26
ECL Exemplary Claim: 1
DRWN 0 Drawing Figure(s); 0 Drawing Page(s)
LN.CNT 988
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention is directed to a **pharmaceutical** composition comprising a **pharmaceutically** effective amount of a lipophilic **drug**, in association with a **pharmaceutical** carrier, said carrier comprising a lipophilic **drug** solubilizing effective amount of a propylene glycol monoester of C.sub.6-C.sub.18 fatty acid having at least 60% by weight monoester based on the total weight of the propylene glycol ester and a non-ionic surfactant.

L5 ANSWER 6 OF 8 USPATFULL on STN
AN 2002:99485 USPATFULL
TI Kinase inhibitors
IN Armistead, David M., Sudbury, MA, UNITED STATES
Bemis, Jean E., Arlington, MA, UNITED STATES
DiPietro, Lucian V., Gloucester, MA, UNITED STATES
Geuns-Meyer, Stephanie D., Medford, MA, UNITED STATES
Habgood, Gregory J., Merrimac, MA, UNITED STATES
Kim, Joseph L., Wayland, MA, UNITED STATES
Nunes, Joseph J., Andover, MA, UNITED STATES
Patel, Vinod F., Acton, MA, UNITED STATES
Toledo-Sherman, Leticia M., Somerville, MA, UNITED STATES
PI US 2002052386 A1 20020502
US 2003004174 A9 20030102
AI US 2001-785599 A1 20010216 (9)
PRAI US 2000-183256P 20000217 (60)
DT Utility
FS APPLICATION
LREP U.S. Patent Operation/JDH, AMGEN INC., Dept. 4300, M/S 27-4-A, One Amgen Center Drive, Thousand Oaks, CA, 91320-1799
CLMN Number of Claims: 29
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 2471
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention relates to inhibitors of kinases, compositions comprising the inhibitors, and methods of using the inhibitors and inhibitor compositions. The inhibitors and compositions comprising them are useful for treating disease or disease symptoms. The invention also provides for methods of making kinase inhibitor compounds, methods of inhibiting kinase activity, and methods for treating disease or disease symptoms.

L5 ANSWER 7 OF 8 USPATFULL on STN
AN 2000:54072 USPATFULL
TI **Pharmaceutical** composition comprising cyclosporin in association with a carrier in a self-emulsifying **drug** delivery

system
IN Mulye, Nirmal, Long Beach, NY, United States
PA Pharmasolutions, Inc., Cranbury, NJ, United States (U.S. corporation)
PI US 6057289 20000502
AI US 1999-303158 19990430 (9)
DT Utility
FS Granted
EXNAM Primary Examiner: Jordan, Kimberly
LREP Scully, Scott, Murphy & Presser
CLMN Number of Claims: 28
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 742
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invent is directed to a **pharmaceutical** composition comprising a **pharmaceutically** effective amount of cyclosporin in association with a **pharmaceutical** carrier, said carrier comprising a **drug** solubilizing effective amount of a fatty acid having 6-22 carbon atoms and a non-ionic surfactant.

L5 ANSWER 8 OF 8 USPATFULL on STN
AN 1999:124497 USPATFULL
TI Self-emulsifiable formulation producing an **oil**-in-water **emulsion**
IN Benita, Simon, Mevasseret Zion, Israel
Kleinstern, Jackie, Jerusalem, Israel
Gershanik, Tatyana, Jerusalem, Israel
PA Yissum Research Development Company of the Hebrew University of Jerusalem, Jerusalem, Israel (non-U.S. corporation)
PI US 5965160 19991012
WO 9633697 19961031
AI US 1998-930854 19980109 (8)
WO 1995-FR531 19950424
19980109 PCT 371 date
19980109 PCT 102(e) date
DT Utility
FS Granted
EXNAM Primary Examiner: Rose, Shep K.
LREP Helfgott & Karas, P.C.
CLMN Number of Claims: 22
ECL Exemplary Claim: 1
DRWN 6 Drawing Figure(s); 6 Drawing Page(s)
LN.CNT 895
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A self-emulsifying oily formulation (SEOF) comprising an **oil** component and a surfactant, the SEOF being characterized in that the **oil** component comprises an oily carrier and a cationic lipid and optionally, a lipophilic oily fatty alcohol, the **oil**-in-water **emulsion** which forms upon mixture of the SEOF, having oily droplets which are positively charged.

=> s l3 and Egbaria, K/au
L6 0 L3 AND EGBARIA, K/AU

=> s Egbaria,K?/au
L7 64 EGBARIA,K?/AU

=> s l3 and l7
L8 3 L3 AND L7

=> s l3 and Egbaria, K?/au
L9 3 L3 AND EGBARIA, K?/AU

=> s l8 and l9

```
L10           3 L8 AND L9

=> s l3 and Groves, M?/au
L11           3 L3 AND GROVES, M?/AU

=> s l10 and l11
L12           3 L10 AND L11

=> d l12 1-3 bib ab

L12  ANSWER 1 OF 3  CAPLUS  COPYRIGHT 2003 ACS on STN
AN   2003:173386  CAPLUS
DN   138:193311
TI   Spontaneous emulsions containing cyclosporine
IN   Egbaria, Kamel F.; Groves, Michael J.
PA   Morton Grove Pharmaceuticals, Inc., USA
SO   PCT Int. Appl., 9 pp.
     CODEN: PIXXD2
DT   Patent
LA   English
FAN.CNT 1
     PATENT NO.         KIND  DATE          APPLICATION NO.  DATE
     ---------------    ----  --------      ---------------  --------
PI   WO 2003017947      A2    20030306      WO 2002-US27531  20020829
         W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
            CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
            GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
            LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
            PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ,
            UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU,
            TJ, TM
         RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG,
            CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL,
            PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR,
            NE, SN, TD, TG
     US 2003049280      A1    20030313      US 2001-943687   20010831
PRAI US 2001-943687     A     20010831
AB   A pharmaceutical compn. contains cyclosporine as the
     active ingredient. More specifically, the compn. is an orally
     administered pharmaceutical formulation in the form of a
     spontaneous emulsion comprising cyclosporine,
     ethanol, Et oleate and polyoxyethylene glycerol
     trioleate. A method for prepg. an orally administered
     pharmaceutical compn. involves first dissolving
     cyclosporine in ethanol. Polyoxyethylene glycerol
     trioleate and an oil component are then added, mixed and dild.
     in an aq. media to form a spontaneous emulsion. Thus, a
     formulation contained cyclosporine 10, EtOH 18, PEG trioleate
     24.5, and Et oleate 47.5 g.

L12  ANSWER 2 OF 3  USPATFULL on STN
AN     2003:70995  USPATFULL
TI     Spontaneous emulsions containing cyclosporine
IN     Egbaria, Kamel F., Gurnee, IL, UNITED STATES
         Groves, Michael J., Deerfield, IL, UNITED STATES
PI     US 2003049280      A1   20030313
AI     US 2001-943687     A1   20010831 (9)
DT     Utility
FS     APPLICATION
LREP   RATNER AND PRESTIA, Suite 301, One Westlakes, Berwyn, P.O. Box 980,
       Valley Forge, PA, 19482-0980
CLMN   Number of Claims: 30
ECL    Exemplary Claim: 1
DRWN   No Drawings
LN.CNT 288
```

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A **pharmaceutical** composition contains **cyclosporine** as the active ingredient. More specifically, the composition is an **orally** administered **pharmaceutical** formulation in the form of a spontaneous **emulsion** comprising **cyclosporine**, **ethanol** ethyl **oleate** and polyoxyethylene glycerol trioleate. A method for preparing an **orally** administered **pharmaceutical** composition involves first dissolving **cyclosporine** in **ethanol**. Polyoxyethylene glycerol trioleate and an **oil** component are then added, mixed and diluted in an aqueous media to form a spontaneous **emulsion**.

L12 ANSWER 3 OF 3 WPIDS COPYRIGHT 2003 THOMSON DERWENT on STN

AN 2003-381396 [36] WPIDS

DNC C2003-101154

TI An **orally** administered **cyclosporine** composition which forms a spontaneous **emulsion** comprises **cyclosporine**, **ethanol**, polyoxyethyleneglycerol trioleate and an **oil**.

DC A96 B04 B07

IN **EGBARIA, K F**; **GROVES, M J**

PA (EGBA-I) EGBARIA K F; (GROV-I) GROVES M J; (MORT-N) MORTON GROVE PHARM INC

CYC 101

PI WO 2003017947 A2 20030306 (200336)* EN 9p

RW: AT BE BG CH CY CZ DE DK EA EE ES FI FR GB GH GM GR IE IT KE LS LU MC MW MZ NL OA PT SD SE SK SL SZ TR TZ UG ZM ZW

W: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG UZ VC VN YU ZA ZM ZW

US 2003049280 A1 20030313 (200336)

ADT WO 2003017947 A2 WO 2002-US27531 20020829; US 2003049280 A1 US 2001-943687 20010831

PRAI US 2001-943687 20010831

AB WO2003017947 A UPAB: 20030609

NOVELTY - An **orally** administered composition comprising **cyclosporine**, **ethanol**, polyoxyethylene glycerol trioleate and an **oil** component is new.

DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included for:

(1) an **orally** administered composition comprising **cyclosporine**, **ethanol**, polyoxyethylene glycerol trioleate and ethyl **oleate** in a weight ratio of 5:18:25.9:50.1 to about 15:16:23.1:44.9; and

(2) preparing an **orally** administered composition by dissolving **cyclosporine** in **ethanol** to form a solution, combining polyoxyethylene glycerol trioleate and an **oil** component with the solution to form a mixture and diluting the mixture with an aqueous media to allow formation of a spontaneous **emulsion**.

ACTIVITY - Immunosuppressive; Antiinflammatory; Protozoacide.

MECHANISM OF ACTION - None given.

USE - **Cyclosporines** have immunosuppressive and anti-inflammatory activity. They may be used to suppress immunological reactions to transplanted organs or tissue, to suppress hematological disorders e.g. anemia, various autoimmune diseases e.g. systemic lupus erythematosus and idiopathic malabsorption syndrome and inflammatory diseases e.g. arthritis and rheumatoid disorders. **Cyclosporine** is also used to treat protozoal diseases e.g. malaria and schistosomiasis and it has also been used recently in chemotherapy.

ADVANTAGE - **Cyclosporine** has low water solubility and so is difficult to formulate for **oral** administration, the present composition overcomes this disadvantage.

Dwg.0/0

```
=> d his

     (FILE 'HOME' ENTERED AT 14:54:42 ON 30 SEP 2003)

     FILE 'MEDLINE, CAPLUS, BIOSIS, BIOTECHDS, EMBASE, USPATFULL, WPIDS'
     ENTERED AT 14:55:08 ON 30 SEP 2003
L1          1256 S CYCLOSPORINE? AND (ETHANO? OR ETHYL(W)ALCOHOL? OR POLYETHYLEN
L2          1254 S L1 AND (MEDIC? OR THERAP? OR DRUG? OR PHARM?)
L3          1103 S L2 AND (ORAL? OR MOUTH OR PER OS)
L4             3 S L3 AND (SPONTANEOUS(W)EMULSION?)
L5             8 S L3 AND (SELF EMULSIFYING DRUG DELIVER SYSTEM OR SEDDS)
L6             0 S L3 AND EGBARIA, K/AU
L7            64 S EGBARIA,K?/AU
L8             3 S L3 AND L7
L9             3 S L3 AND EGBARIA, K?/AU
L10            3 S L8 AND L9
L11            3 S L3 AND GROVES, M?/AU
L12            3 S L10 AND L11

=>

---Logging off of STN---


=>
Executing the logoff script...


=> LOG Y

STN INTERNATIONAL LOGOFF AT 15:14:07 ON 30 SEP 2003
```